Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Krystal Biotech, Inc. - Common Stock
(NQ:
KRYS
)
251.77
+2.38 (+0.95%)
Streaming Delayed Price
Updated: 12:14 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Krystal Biotech, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop
↗
December 19, 2025
The timing looks painful, but the fundamentals tell a more complicated story about why long-term investors are still paying attention.
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Is IPG Photonics Stock a Buy as One Fund Builds a $9 Million Stake in the Firm?
↗
December 19, 2025
A sharp rebound in margins and profitability is testing whether patience can finally pay off for investors willing to look past years of volatility.
Via
The Motley Fool
Topics
Regulatory Compliance
Why One Fund Has an $8.5 Million Bet on Five9 Despite a 50% One-Year Stock Collapse
↗
December 19, 2025
The stock’s collapse tells one story, but the underlying business metrics suggest a very different long-term setup.
Via
The Motley Fool
Topics
Regulatory Compliance
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
Earnings Scheduled For August 4, 2025
↗
August 04, 2025
Via
Benzinga
Earnings Outlook For Krystal Biotech
↗
August 01, 2025
Via
Benzinga
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock
↗
December 03, 2025
One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?
↗
December 03, 2025
One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.
Via
The Motley Fool
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet?
↗
December 03, 2025
Soleno just turned profitable for the first time—right as a major fund made its move.
Via
The Motley Fool
Topics
Regulatory Compliance
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today
↗
November 12, 2025
Via
Benzinga
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
November 10, 2025
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
What's Driving the Market Sentiment Around Krystal Biotech Inc?
↗
November 06, 2025
Via
Benzinga
Krystal Biotech (KRYS) Q3 2025 Earnings Transcript
↗
November 03, 2025
Krystal Biotech (KRYS) Q3 2025 Earnings Transcript
Via
The Motley Fool
Topics
Earnings
Krystal Biotech (KRYS) Q3 2025 Earnings Top Estimates on Strong VYJUVEK Sales
↗
November 03, 2025
Krystal Biotech's Q3 2025 earnings crushed estimates, with EPS of $2.66 and $97.8M revenue. Strong VYJUVEK sales and global expansion in Europe and Japan drive growth.
Via
Chartmill
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today
↗
October 31, 2025
Via
Benzinga
Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts
↗
October 17, 2025
Via
Benzinga
$100 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today
↗
October 16, 2025
Via
Benzinga
Insider Confidence Shines: Krystal Biotech and Growth Stocks with Strong Management Stakes Navigate Volatile Markets
October 15, 2025
The U.S. stock market is currently a landscape of contrasting forces, with robust bank earnings providing a bedrock of stability against the backdrop of persistent trade tensions with China and...
Via
MarketMinute
Topics
Artificial Intelligence
World Trade
What's Driving the Market Sentiment Around Krystal Biotech Inc?
↗
October 10, 2025
Via
Benzinga
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner
↗
September 30, 2025
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.
Via
Benzinga
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
↗
September 25, 2025
Krystal Biotech (NASDAQ: KRYS) has outperformed the market over the past 5 years by 16.54% on an annualized basis producing an average annual return of 31.18%. Currently, Krystal Biotech has a market...
Via
Benzinga
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
↗
September 18, 2025
Via
Benzinga
FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin
↗
September 15, 2025
The FDA approved Krystal Biotech's Vyjuvek label update, expanding treatment to newborns and offering flexible wound care based on real-world patient data.
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
↗
September 02, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Krystal Biotech Through 10 Analysts
↗
August 22, 2025
Via
Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
↗
August 18, 2025
Via
Benzinga
What 8 Analyst Ratings Have To Say About Krystal Biotech
↗
August 05, 2025
Via
Benzinga
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results
↗
August 04, 2025
Via
Benzinga
Krystal (KRYS) Q2 Profit Jumps 143%
↗
August 04, 2025
Via
The Motley Fool
KRYSTAL BIOTECH INC (NASDAQ:KRYS) Q2 2025 Earnings Beat Estimates as VYJUVEK Drives Strong Revenue Growth
↗
August 04, 2025
Krystal Biotech (KRYS) Q2 2025 earnings beat estimates with $96M revenue and $1.29 EPS, driven by VYJUVEK success. Shares rose 4% pre-market.
Via
Chartmill
Topics
Earnings
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.